VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

PHR.US

26.11

+3.08%↑

Search

Medtronic PLC

Cerrado

SectorSanidad

88.96 0.59

Resumen

Variación precio

24h

Actual

Mínimo

87.4

Máximo

88.97

Métricas clave

By Trading Economics

Ingresos

32M

1.3B

Ventas

-111M

8.3B

P/B

Media del Sector

27.396

63.778

BPA

1.39

Rentabilidad por dividendo

3.12

Margen de beneficios

15.798

Empleados

95,000

EBITDA

-40M

2.4B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+8.94% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.12%

2.39%

Próximas Ganancias

22 may 2025

Fecha Próximo Dividendo

11 abr 2025

Próxima Fecha de Ex Dividendo

27 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-5.4B

115B

Apertura anterior

88.37

Cierre anterior

88.96

Noticias sobre sentimiento de mercado

By Acuity

23%

77%

57 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Medtronic PLC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 feb 2025, 12:24 UTC

Ganancias

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

19 nov 2024, 12:27 UTC

Ganancias

Medtronic Narrows Fiscal Year Guidance as 2Q Tops Views

27 feb 2025, 10:30 UTC

Principales Noticias

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18 feb 2025, 11:47 UTC

Ganancias

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18 feb 2025, 11:46 UTC

Ganancias

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q Adj EPS $1.39 >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q Neuroscience Portfolio Rev $2.46B >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q Net $1.29B >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q Diabetes Rev $694M >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q Medical Surgical Portfolio Rev $2.07B >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q Cardiovascular Portfolio Rev $3.04B >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q Organic Revenue Up 4.1% >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q EPS $1.01 >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

18 feb 2025, 11:45 UTC

Ganancias

Medtronic 3Q Sales $8.29B >MDT

18 feb 2025, 10:01 UTC

Ganancias
Acciones populares

Stocks to Watch Tuesday: Intel, Baidu, Constellation Brands -- WSJ

21 ene 2025, 19:15 UTC

Principales Noticias

Medtronic Hires CFO From Renault -- Update

21 ene 2025, 12:17 UTC

Principales Noticias

Medtronic Hires CFO From Renault

19 nov 2024, 12:12 UTC

Ganancias

Medtronic Narrows FY Guidance as 2Q Tops Views

19 nov 2024, 11:46 UTC

Ganancias

Medtronic Sees High-Single-Digit Adjusted EPS Growth in 2nd Half of FY25 >MDT

19 nov 2024, 11:46 UTC

Ganancias

Medtronic Narrows FY25 Organic Rev Growth View to 4.75%-5% From 4.5%-5% >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic 2Q Medical Surgical Portfolio Rev $2.13B >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic 2Q Adj EPS $1.26 >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic 2Q Diabetes Rev $686M >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic 2Q Neuroscience Portfolio Rev $2.45B >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic 2Q Net $1.27B >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic 2Q Organic Revenue Up 5.0% >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic 2Q Cardiovascular Portfolio Rev $3.1B >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic Sees FY Adj EPS $5.44-Adj EPS $5.50 >MDT

19 nov 2024, 11:45 UTC

Ganancias

Medtronic 2Q Sales $8.4B >MDT

Comparación entre iguales

Cambio de precio

Medtronic PLC previsión

Precio Objetivo

By TipRanks

8.94% repunte

Estimación a 12 Meses

Media 96.4 USD  8.94%

Máximo 109 USD

Mínimo 85 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Medtronic PLC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

9

Comprar

9

Mantener

1

Vender

Puntuación técnica

By Trading Central

88.02 / 90.29Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Sentimiento

By Acuity

57 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.